Brings Decades of
At Pfizer, Altstiel served as Vice President Neuroscience Clinical Development, Neuroscience Therapeutic Area Clinical Lead from 2007-2013. In this role, he was responsible for the selection, development, and oversight of multiple preclinical studies and research. Altstiel also served as Head of the Neuroscience Technical Review Committee that approved clinical research and development programs.
“We are thrilled that Larry has decided to join our company as we enter
this critical phase of our trials,” said
Prior to joining Pfizer, Altstiel held senior research and management
roles at
vTv’s lead drug candidate for the treatment of Alzheimer’s disease, azeliragon,
is currently in its Phase 3 trial with more than 80 enrollment sites
initiated throughout the U.S. and
In addition to vTv’s Alzheimer’s disease program, the Company has two potential best-in-class oral diabetes treatments currently in trials with expected data read outs in 2016.
“I'm looking forward to joining this outstanding team, which is focused on addressing such significant unmet medical needs,” Altstiel stated. “The positive signs from previous trials have put this company on a path for potentially extraordinary breakthroughs and I am excited to be a part of it.”
About
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Alzheimer’s Disease: STEADFAST Study
In
For more information on the STEADFAST study, click: http://www.steadfastalzheimers.com/
Diabetes: AGATA Study
In
For more information about the AGATA Study, click: http://www.myagata.com/
Diabetes: LOGRA Study
The LOGRA Phase 2 study will evaluate TTP273, which would be an orally bioavailable, potent, non-peptide agonist of GLP-1R for the treatment of type 2 diabetes. This molecule is the second generation from a path-finder molecule TTP054, and it is anticipated to provide excellent glycemic control and an attractive safety profile for the treatment of type 2 diabetes. The completed Phase 1b trial in TTP273 demonstrated robust effects on postprandial & fasting glucose.
The LOGRA study is expected to start in the beginning of 2016 with data expected to read out in late-2016.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151202005183/en/
Source:
Investors:
The Trout Group
Josh Barer, 646-378-2948
jbarer@troutgroup.com
or
Media:
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com